Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Haematologica"
DOI: 10.3324/haematol.2021.278311
Abstract: High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment of chemosensitive relapsed classical Hodgkin lymphoma (cHL), although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR cHL patients treated with… read more here.
Keywords: dose chemotherapy; hodgkin lymphoma; gembumel; high dose ... See more keywords